Inventiva Reports Preliminary Financial Results for 2025

Inventiva, a biopharmaceutical company focused on oral therapies for metabolic dysfunction-associated steatohepatitis (MASH), has released preliminary 2025 financial results. As of December 31, 2025, the company's cash and cash equivalents stood at €99.3 million, with short-term deposits of €131.6 million. Revenue for 2025 was €4.5 million, a decline from €9.2 million in 2024.

The company completed a U.S. public offering, raising approximately $172.5 million (€149 million), supporting a cash runway through the first quarter of 2027. Despite a 4% reduction in R&D expenses to €86.9 million, operating cash use increased by 22%, mainly due to strategic pipeline prioritization and increased administrative costs.

Inventiva anticipates financing operations through mid-2027, potentially extending to Q3 2027 with warrant proceeds. Audited results for the fiscal year 2025 are expected on March 30, 2026.